Press Releases March 30, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026

KANZHUN LIMITED Advances Share Repurchase Program, Spending Over RMB576 Million in 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (BOSS Zhipin) announced the continuation of its share repurchase program, having spent approximately RMB34.5 million to buy back 744,334 shares on March 30, 2026. Total repurchases for the year so far exceed RMB576 million, demonstrating the company's focus on enhancing shareholder value.

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Over RMB576 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has repurchased over RMB576 million worth of shares year-to-date in 2026.
  • The company repurchased 744,334 ordinary shares on March 30 using RMB34.5 million.
  • The ongoing share buyback program highlights management's commitment to returning value to shareholders.
  • The company's actions impact the technology and internet sectors, particularly online recruitment and HR services markets.

BEIJING, March 31, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB34.5 million to repurchase 744,334 ordinary shares on March 30. Year-to-date in 2026, the Company has deployed over RMB576 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued allocation of funds to share repurchases may limit capital available for business expansion or R&D.
  • Market volatility could affect the timing and scale of repurchases.
  • Changes in regulatory environment affecting stock buybacks could impact the program.

More from Press Releases

HII Promotes Greg Ennis to Chief Financial Officer of Mission Technologies Oct 2, 2026 Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 Oct 2, 2026 Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus Oct 2, 2026 CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 Oct 2, 2026 Meet FORTITUDE™: The Single Chip Supercharging Data Speed and System Performance Oct 2, 2026